143 related articles for article (PubMed ID: 26841786)
21. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
Jackson R
J Hum Hypertens; 1998 Sep; 12(9):607-13. PubMed ID: 9783489
[TBL] [Abstract][Full Text] [Related]
22. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
[TBL] [Abstract][Full Text] [Related]
24. Hypertension: Cost-effectiveness of 2014 guidelines.
Duarte JH
Nat Rev Cardiol; 2015 Apr; 12(4):194. PubMed ID: 25687778
[No Abstract] [Full Text] [Related]
25. Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial.
Jafar TH; Jehan I; de Silva HA; Naheed A; Gandhi M; Assam P; Finkelstein EA; Quigley HL; Bilger M; Khan AH; Clemens JD; Ebrahim S; Turner EL; ; Kasturiratne A
Trials; 2017 Jun; 18(1):272. PubMed ID: 28606184
[TBL] [Abstract][Full Text] [Related]
26. [Official recommendations and guidelines for the management and reimbursement of severe hypertension as a chronic disease].
Boivin JM; Zannad F
Presse Med; 2009 Apr; 38(4):652-60. PubMed ID: 19249189
[TBL] [Abstract][Full Text] [Related]
27. Cost-effective therapy for hypertension.
Barrie W
West J Med; 1996 Apr; 164(4):303-9. PubMed ID: 8732729
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
29. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
[TBL] [Abstract][Full Text] [Related]
30. Improving cost-effectiveness of hypertension management at a community health centre.
Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
[TBL] [Abstract][Full Text] [Related]
31. Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension.
Klarenbach SW; McAlister FA; Johansen H; Tu K; Hazel M; Walker R; Zarnke KB; Campbell NR;
Can J Cardiol; 2010 May; 26(5):e158-63. PubMed ID: 20485695
[TBL] [Abstract][Full Text] [Related]
32. Impact of early initiation of antihypertensive medications for patients with hypertension or elevated blood pressure.
Han X; McCombs J; Chu M; Dougherty JS; Fox DS
J Hypertens; 2019 Jun; 37(6):1276-1284. PubMed ID: 30624365
[TBL] [Abstract][Full Text] [Related]
33. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoeconomic burden of undertreating hypertension.
Degli Esposti L; Valpiani G
Pharmacoeconomics; 2004; 22(14):907-28. PubMed ID: 15362928
[TBL] [Abstract][Full Text] [Related]
35. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Grover SA; Coupal L; Zowall H
Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
[TBL] [Abstract][Full Text] [Related]
36. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure.
Siegel D; Lopez J
JAMA; 1997 Dec; 278(21):1745-8. PubMed ID: 9388150
[TBL] [Abstract][Full Text] [Related]
37. Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of Hypertension/European Society of Cardiology hypertension guidelines.
Marques-Vidal P; Waeber G; Waeber B; Vollenweider P
J Hypertens; 2015 Apr; 33(4):868-73. PubMed ID: 25915892
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of intensive hypertension control in China.
Xie X; He T; Kang J; Siscovick DS; Li Y; Pagán JA
Prev Med; 2018 Jun; 111():110-114. PubMed ID: 29525577
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
